Moxie Dwight

CIK 00018033751 companyNASHVILLE, TN

SEC Profile

Transactions

Companies

Filings

CIK

0001803375

Recent Transactions

32 trades

Disposition to Issuer
Revance Therapeutics, Inc.
Common Stock
2025-02-06−95,979→ 0 total
Disposition to Issuer
Revance Therapeutics, Inc.
Common Stock
2025-02-06−18,125→ 0 total
Award
Revance Therapeutics, Inc.
Common Stock
2025-02-06+18,125→ 18,125 total
Disposition from Tender
Revance Therapeutics, Inc.
Common Stock
2025-02-04$3.65/sh−47,815→ 95,979 total
Award
Revance Therapeutics, Inc.
Common Stock
2025-02-03+5,979→ 143,794 total
Sale
Revance Therapeutics, Inc.
Common Stock
2024-03-18$5.04/sh−8,125→ 137,815 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2024-03-15$5.30/sh−3,269→ 145,940 total
Award
Revance Therapeutics, Inc.
Common Stock
2024-02-29+15,143→ 149,209 total
Award
Revance Therapeutics, Inc.
Common Stock
2024-01-31+90,000→ 134,066 total
Award
Revance Therapeutics, Inc.
Performance Stock Units
2024-01-31+135,000→ 135,000 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-09-06$17.06/sh−11,000→ 44,066 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-09-05$17.81/sh−23,853→ 55,066 total
Award
Revance Therapeutics, Inc.
Common Stock
2023-08-11+19,346→ 88,511 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2023-08-11$18.91/sh−9,592→ 78,919 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-05-15$34.55/sh−21,401→ 69,165 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2023-03-15$30.65/sh−7,330→ 48,217 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-03-09$31.59/sh−18,496→ 55,547 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2023-01-31+43,774→ 43,774 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-09-22+42,349→ 74,043 total
Sale
Revance Therapeutics, Inc.
Common Stock
2022-09-14$27.07/sh−11,000→ 31,694 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2022-03-15$15.79/sh−2,229→ 42,694 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2022-03-15$15.79/sh−2,881→ 44,923 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2022-02-02+68,093→ 68,093 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-02-02+42,349→ 90,566 total
Sale
Revance Therapeutics, Inc.
Common Stock
2021-09-27$30.00/sh−1,675→ 47,804 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2021-03-15$27.73/sh−2,881→ 49,479 total
Award
Revance Therapeutics, Inc.
Common Stock
2021-02-02+19,346→ 52,360 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2021-02-02+35,002→ 35,002 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2020-09-30$25.14/sh−4,236→ 33,014 total
Award
Revance Therapeutics, Inc.
Common Stock
2020-09-30+12,250→ 37,250 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2020-02-18+170,000→ 170,000 total
Award
Revance Therapeutics, Inc.
Common Stock
2020-02-18+25,000→ 25,000 total

Companies

Revance Therapeutics, Inc.
CLO & GC

Recent Filings

Address

C/O REVANCE THERAPEUTICS, INC. 1222 DEMONBREUN STREET, 20TH FLOOR

NASHVILLE, TN, 37203

View on SEC.gov